Erasca (ERAS) Gains from Sales and Divestitures (2021 - 2022)
Erasca (ERAS) reported Gains from Sales and Divestitures of $205996.0 for Q4 2022, down 40.25% on a YoY basis from $344790.0 in Q4 2021, and little changed quarter-over-quarter from $205996.0 in Q3 2022.
Erasca (ERAS) Gains from Sales and Divestitures (2021 - 2022) Analysis & Trends
Erasca has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $205996.0 in Q4 2022.
- For the quarter ending Q4 2022, Gains from Sales and Divestitures fell 40.25% year-over-year to $205996.0; the trailing twelve-month figure through Dec 2022 stood at $205996.0 (down 40.25% YoY), and the FY2022 full-year result was $205996.0, down 40.25% from the prior year.
- Gains from Sales and Divestitures for Q4 2022 stood at $205996.0, roughly flat from $205996.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $344790.0 in Q4 2021, with the low at $86198.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Erasca | 4.28 Bn | 4.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 205,996.00 |
| Dec 31, 2022 | 205,996.00 |
| Sep 30, 2022 | 205,996.00 |
| Sep 30, 2022 | 205,996.00 |
| Jun 30, 2022 | 167,186.00 |
| Jun 30, 2022 | 167,186.00 |
| Mar 31, 2022 | 86,198.00 |
| Mar 31, 2022 | 86,198.00 |
| Dec 31, 2021 | 344,790.00 |
| Dec 31, 2021 | 344,790.00 |
| Sep 30, 2021 | 258,592.00 |
| Sep 30, 2021 | 258,592.00 |
| Jun 30, 2021 | 172,394.00 |
| Jun 30, 2021 | 172,394.00 |